InvestorsHub Logo
Followers 23
Posts 911
Boards Moderated 0
Alias Born 10/22/2015

Re: Reyeton post# 80967

Friday, 11/25/2016 8:06:22 PM

Friday, November 25, 2016 8:06:22 PM

Post# of 463682
Biogen has set the bar low for Aducanumab (what marketing genius came up with that name?) to achieve "success". All the enrollees have only mild cognitive impairment or, at worst, mild Alzheimers. Way to stick your neck out there Biogen. And the drug has a significant side effect: brain swelling. When my sister's bf had meningitis he had brain swelling and the pain from that he said was excruciating like the worst headache imaginable.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News